Unknown

Dataset Information

Brief Report: Heterogeneity of Acquired Resistance Mechanisms to Osimertinib and Savolitinib.


ABSTRACT:

Introduction

MET amplification is a frequently observed mechanism of resistance to osimertinib, and coinhibition strategy of MET and EGFR revealed promising results in recent clinical trials. Nevertheless, acquired resistance mechanisms to combined EGFR and MET inhibition are poorly understood. In this study, we investigated the mechanisms of acquired resistance to osimertinib and savolitinib by using pretreatment and post-treatment tissue analysis.

Methods

Whole-exome sequencing was performed in EGFR-mutant, MET-amplified patients who received osimertinib and savolitinib using tissues obtained both before and after therapy. All patients achieved partial response or durable stable disease to osimertinib and savolitinib before developing acquired resistan

SUBMITTER: Lim SM 

PROVIDER: S-EPMC8474358 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature